Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.39 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3430556 | 0.98 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| [1,4']Bipiperidinyl SCHEMBL29018730 | 0.91 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| SCHEMBL3402669 | 0.87 | HTR6 (0.56) | L3MBTL3L3MBTL1MBTD1HTR6TP53BP1 | |
| SCHEMBL3400390 | 0.87 | HTR6 (0.56) | L3MBTL3L3MBTL1MBTD1HTR6TP53BP1 | |
| [1,4']Bipiperidinyl SCHEMBL28299957 | 0.86 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| [1,4']Bipiperidinyl SCHEMBL25285816 | 0.86 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| [1,4']Bipiperidinyl SCHEMBL42685 | 0.84 | HTR6 (0.52) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| SCHEMBL3159634 | 0.84 | HTR6 (0.52) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| [1,4']Bipiperidinyl SCHEMBL352141 | 0.84 | HTR6 (0.52) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 | |
| [1,4']Bipiperidinyl SCHEMBL27743042 | 0.83 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1MBTD1HRH3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101005840-A | Process for preparing camptothecin derivatives, novel intermediates and compounds thereof | CHATHAM BIOTEC LTD (CA) | 2007-07-25 | — | — | CN | claimed |
| CN-112759603-B | Podophyllotoxin derivative and application thereof | 加州太平洋医疗中心 | 2022-09-09 | — | — | CN | disclosed |
| CN-112759603-A | Podophyllotoxin derivative and application thereof | 加州太平洋医疗中心 | 2021-05-07 | — | — | CN | disclosed |
| CN-106937529-B | Podophyllotoxin derivative and application thereof | 加州太平洋医疗中心 | 2021-02-05 | — | — | CN | disclosed |
| CN-106937529-A | Podophyllotoxin derivative and application thereof | 加州太平洋医疗中心 | 2017-07-07 | — | — | CN | disclosed |
| WO-2008035377-A2 | NOVEL INTERMEDIATES FOR THE PREPARATION OF CAMPTOTHECIN ANALOGUES | SHILPA MEDICARE LTD. (IN) | 2008-03-27 | — | — | WO | disclosed |
| US-20070208050-A1 | PROCESS FOR PREPARING IRINOTECAN | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-09-06 | — | — | US | disclosed |
| CN-101005840-A | Process for preparing camptothecin derivatives, novel intermediates and compounds thereof | CHATHAM BIOTEC LTD (CA) | 2007-07-25 | — | — | CN | disclosed |
| US-7135502-B1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2006-11-14 | — | — | US | disclosed |
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | ANGIOGENE PHARMACEUTICALS LTD. | 2006-06-15 | — | — | US | disclosed |
| EP-1140745-B1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARM LTD (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1140745-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | Angiogene Pharmaceuticals Ltd (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040529-A1 | COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS | ANGIOGENE PHARMACEUTICALS LTD. (GB) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128633-A1 | Colchinol derivatives as vascular damaging agents | NR1H3, NR1H2, NR1H4 | L3MBTL3 2564/4885L3MBTL1 2659/4885MBTD1 3259/4885 |
| US-20070208050-A1 | PROCESS FOR PREPARING IRINOTECAN | SI, TYMP, TOP1 | L3MBTL3 4774/4885L3MBTL1 4799/4885MBTD1 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.